Cargando…

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer

BACKGROUND: Bacillus Calmette-Guerin (BCG) is the most effective intravesical therapy for non-muscle invasive bladder cancer (NMIBC), but patients can fail or supply shortages can develop. For BCG failures, radical cystectomy is recommended. However, in patients who desire bladder preservation or ar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steinberg, Ryan L., Thomas, Lewis J., O’Donnell, Michael A., Nepple, Kenneth G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2015
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218180/ https://www.ncbi.nlm.nih.gov/pubmed/30561441 http://dx.doi.org/10.3233/BLC-150008

Ejemplares similares

Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
por: McElree, Ian M., et al.
Publicado: (2023)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Intravesical docetaxel for high-risk non-muscle invasive bladder cancer after Bacillus Calmette-Guérin failure
por: Shantharam, Govind, et al.
Publicado: (2021)

Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial
por: Jayant, Kumar, et al.
Publicado: (2015)

Intravesical chemotherapy in non-muscle-invasive bladder cancer
por: Porten, Sima P., et al.
Publicado: (2015)

Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor
por: Shao, Li-jun, et al.
Publicado: (2022)

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma
por: Du, Zheng, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial
por: Li, Rongxin, et al.
Publicado: (2020)

The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer
por: Douglass, Laura, et al.
Publicado: (2016)

Device-assisted intravesical therapy for non-muscle invasive bladder cancer
por: Hendricksen, Kees
Publicado: (2019)

Intravesical gemcitabine as bladder‐preserving treatment for BCG unresponsive non‐muscle‐invasive bladder cancer. Results from a single‐arm, open‐label study
por: Hurle, Rodolfo, et al.
Publicado: (2020)

Intravesical Treatments of Bladder Cancer: Review
por: Shen, Zancong, et al.
Publicado: (2008)

The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guérin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis
por: Ye, Ziqi, et al.
Publicado: (2018)

RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy
por: Yang, Zhenxing, et al.
Publicado: (2019)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
por: Nahhat, Fouad, et al.
Publicado: (2022)

Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease
por: Steinberg, Ryan L., et al.
Publicado: (2016)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
por: James, Christopher, et al.
Publicado: (2023)

Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence
por: Zhang, Jianglei, et al.
Publicado: (2021)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

Novel intravesical therapeutics in the treatment of non-muscle invasive bladder cancer: Horizon scanning
por: Ward, Kelly, et al.
Publicado: (2022)

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy
por: Serretta, Vincenzo, et al.
Publicado: (2015)

Evaluating the safety of intraoperative instillation of intravesical chemotherapy at the time of nephroureterectomy
por: Moriarty, Michael A., et al.
Publicado: (2015)

Redefining the role of immediate intravesical instillation of mitomycin C in non-muscle invasive bladder cancer
por: Batura, Deepak
Publicado: (2018)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Management of BCG non-responders with fixed dose intravesical gemcitabine in superficial transitional cell carcinoma of urinary bladder
por: Mohanty, N. K., et al.
Publicado: (2008)

Treatment options in non-muscle-invasive bladder cancer after BCG failure
por: Brooks, Nathan A., et al.
Publicado: (2015)

Intravesical immunotherapy in nonmuscle invasive bladder cancer
por: Jokisch, Jan-Friedrich, et al.
Publicado: (2015)

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

High-Risk Non-Muscle-Invasive Bladder Cancer—Therapy Options During Intravesical BCG Shortage
por: Veeratterapillay, Rajan, et al.
Publicado: (2016)

Editorial on the value of an immediate intravesical instillation of mitomycin C in patients with non-muscle-invasive bladder cancer
por: Oosterlinck, Willem, et al.
Publicado: (2018)

Emerging concepts and spectrum of renal injury following Intravesical BCG for non-muscle invasive bladder cancer
por: Mohammed, Azharuddin, et al.
Publicado: (2017)

Renal Granulomatosis Post Intravesical Bacillus Calmette–Guerin Therapy for Non-muscle-invasive Bladder Cancer
por: Tran-Harding, Karen, et al.
Publicado: (2018)

The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer
por: Chen, Jian-Xin, et al.
Publicado: (2023)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer
por: Relouw, Sydney, et al.
Publicado: (2023)

Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis
por: Zhuo, Chuanjun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fbhkrum5hfjj14uak2uqb0kjhh